Kingswood Capital Partners Announces Initial Public Offering Pricing
Kingswood Capital Partners, LLC has officially announced the pricing for an initial public offering (the "Offering") on behalf of its client, WORK Medical Technology Group LTD. (Nasdaq: WOK), a supplier of medical devices. The Offering will consist of 2,000,000 ordinary shares, each priced at US$4.00. This is a significant milestone for the Company as it begins trading under the ticker symbol "WOK."
Details of the Offering and Financial Outlook
The total gross proceeds anticipated from the Offering amount to US$8.00 million, which the Company will receive before any underwriting discounts and related expenses are deducted. This capital injection is expected to support the Company's growth strategies and operational enhancements.
Planned Use of Proceeds
The funds raised through the Offering will be allocated to several essential areas, including upgrading production equipment and increasing production capacity. The Company also intends to invest in the development of masks, various medical consumables, and a range of medical devices. Furthermore, part of the proceeds will be directed towards product marketing, patent acquisitions, working capital, and other general corporate needs.
Management of the Offering and Legal Counsel
The Offering is being conducted on a “firm commitment” basis, with Kingswood Capital Partners serving as the sole book-running manager. Hunter Taubman Fischer & Li LLC is providing legal counsel in the U.S. for the Company, while Ortoli Rosenstadt LLP is fulfilling the same role for Kingswood.
Registration Statements and Compliance Information
A registration statement on Form F-1 related to the Offering has been filed with the U.S. Securities and Exchange Commission (SEC) and has received effective status. The Offering is being executed exclusively through a prospectus that is part of the registration statement. Interested individuals can obtain copies of the prospectus directly from Kingswood.
How to Contact for Prospectus Information
For inquiries regarding the Offering, Kingswood can be reached at their office in Boca Raton, FL. They provide assistance through various channels, including email. Additionally, more documentation related to the Offering can be found on the SEC’s website.
Overview of WORK Medical Technology Group LTD
WORK Medical Technology Group LTD operates within the medical devices sector, concentrating on the development and manufacturing of Class I and II medical devices. The Company has a diverse product portfolio that includes 21 unique products, such as customized masks and other vital medical consumables. Their products have been successfully marketed across 34 provincial-level regions in China and have gained popularity in over 30 countries worldwide.
Commitment to Regulatory Compliance and Product Quality
WORK Medical Technology Group LTD is dedicated to upholding high-quality standards in its manufacturing processes. The Company has earned several quality-related certifications and has registered 17 of its products with the U.S. Food and Drug Administration, thereby enhancing its access to the U.S. market.
About Kingswood Capital Partners
Kingswood, part of the Kingswood Group, is a versatile organization that offers comprehensive wealth management and business-building services tailored for independent financial advisors. The group manages over $14 billion in assets under management (AUM) and supports more than 400 registered representatives, combining the resources of a large financial services firm with the personalized attention of a boutique operation.
Media Contacts
For media inquiries, Kingswood Capital Partners can be contacted through Ryan Sabet, the Director of Acquisition, Recruitment & Strategic Initiatives. He is available via telephone or email for those interested in learning more about Kingswood's services.
Frequently Asked Questions
What is the price of the ordinary shares in the IPO?
The ordinary shares are priced at US$4.00 each in the initial public offering.
How many ordinary shares are being offered?
A total of 2,000,000 ordinary shares are included in the offering.
What will the proceeds from the IPO be used for?
The proceeds will be used to upgrade production equipment, develop new medical products, and cover marketing and operational expenses.
Who is managing the IPO?
Kingswood Capital Partners is the sole book-running manager for the IPO.
Where can interested parties find the prospectus for the offering?
The prospectus can be obtained from Kingswood directly or via the SEC’s website.
